SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Verbeek R) "

Sökning: WFRF:(Verbeek R)

  • Resultat 1-10 av 56
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Thomas, HS, et al. (författare)
  • 2019
  • swepub:Mat__t
  •  
2.
  •  
3.
  • Thoma, B, et al. (författare)
  • An international, interprofessional investigation of the self-reported podcast listening habits of emergency clinicians: A METRIQ Study
  • 2020
  • Ingår i: CJEM. - : Springer Science and Business Media LLC. - 1481-8043 .- 1481-8035. ; 22:1, s. 112-117
  • Tidskriftsartikel (refereegranskat)abstract
    • ObjectivesPodcasts are increasingly being used for medical education. A deeper understanding of usage patterns would inform both producers and researchers of medical podcasts. We aimed to determine how and why podcasts are used by emergency medicine and critical care clinicians.MethodsAn international interprofessional sample (medical students, residents, physicians, nurses, physician assistants, and paramedics) was recruited through direct contact and a multimodal social media (Twitter and Facebook) campaign. Each participant completed a survey outlining how and why they utilize medical podcasts. Recruitment materials included an infographic and study website.Results390 participants from 33 countries and 4 professions (medicine, nursing, paramedicine, physician assistant) completed the survey. Participants most frequently listened to medical podcasts to review new literature (75.8%), learn core material (75.1%), and refresh memory (71.8%). The majority (62.6%) were aware of the ability to listen at increased speeds, but most (76.9%) listened at 1.0 x (normal) speed. All but 25 (6.4%) participants concurrently performed other tasks while listening. Driving (72.3%), exercising (39.7%), and completing chores (39.2%) were the most common. A minority of participants used active learning techniques such as pausing, rewinding, and replaying segments of the podcast. Very few listened to podcasts multiple times.ConclusionsAn international cohort of emergency clinicians use medical podcasts predominantly for learning. Their listening habits (rarely employing active learning strategies and frequently performing concurrent tasks) may not support this goal. Further exploration of the impact of these activities on learning from podcasts is warranted.
  •  
4.
  • Zeiser, R., et al. (författare)
  • Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
  • 2015
  • Ingår i: Leukemia. - : Springer Science and Business Media LLC. - 0887-6924 .- 1476-5551. ; 29:10, s. 2062-2068
  • Tidskriftsartikel (refereegranskat)abstract
    • Despite major improvements in allogeneic hematopoietic cell transplantation over the past decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease (GVHD) cause high mortality. Preclinical evidence indicates the potent anti-inflammatory properties of the JAK1/2 inhibitor ruxolitinib. In this retrospective survey, 19 stem cell transplant centers in Europe and the United States reported outcome data from 95 patients who had received ruxolitinib as salvage therapy for SR-GVHD. Patients were classified as having SR-aGVHD (n = 54, all grades III or IV) or SR-cGVHD (n = 41, all moderate or severe). The median number of previous GVHD-therapies was 3 for both SR-aGVHD (1-7) and SR-cGVHD (1-10). The overall response rate was 81.5% (44/54) in SR-aGVHD including 25 complete responses (46.3%), while for SR-cGVHD the ORR was 85.4% (35/41). Of those patients responding to ruxolitinib, the rate of GVHD-relapse was 6.8% (3/44) and 5.7% (2/35) for SR-aGVHD and SR-cGVHD, respectively. The 6-month-survival was 79% (67.3-90.7%, 95% confidence interval (CI)) and 97.4% (92.3-100%, 95% CI) for SR-aGVHD and SR-cGVHD, respectively. Cytopenia and cytomegalovirus-reactivation were observed during ruxolitinib treatment in both SR-aGVHD (30/54, 55.6% and 18/54, 33.3%) and SR-cGVHD (7/41, 17.1% and 6/41, 14.6%) patients. Ruxolitinib may constitute a promising new treatment option for SR-aGVHD and SR-cGVHD that should be validated in a prospective trial.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 56
Typ av publikation
tidskriftsartikel (44)
konferensbidrag (9)
forskningsöversikt (1)
bokkapitel (1)
Typ av innehåll
refereegranskat (45)
övrigt vetenskapligt/konstnärligt (10)
Författare/redaktör
Blennow, Kaj, 1958 (12)
Verbeek, Marcel M (12)
Visser, Pieter Jelle (12)
Verbeek, M (11)
Zetterberg, Henrik, ... (10)
Tsolaki, Magda (10)
visa fler...
Scheltens, Philip (10)
Teunissen, Charlotte ... (10)
Lleó, Alberto (10)
Parnetti, Lucilla (8)
Mielke, S (7)
van der Flier, Wiesj ... (7)
Soininen, Hilkka (7)
Molinuevo, José Luis (7)
Alcolea, Daniel (7)
Wiltfang, Jens (7)
Engelborghs, Sebasti ... (7)
Fortea, Juan (6)
Fagan, Anne M (6)
Kornhuber, Johannes (6)
Ossenkoppele, Rik (6)
Frisoni, Giovanni B. (6)
Fladby, Tormod (6)
Mattsson, Niklas (6)
Cavedo, Enrica (6)
Schmidt, T. (5)
Wagner, R (5)
Aarsland, Dag (5)
Van Laere, Koen (5)
Vandenberghe, Rik (5)
Jagust, William J. (5)
Marcusson, Jan (5)
Hansson, Oskar (5)
Chen, Kewei (5)
Klein, S. (5)
Rinne, Juha O. (5)
Morris, John C (5)
Rami, Lorena (5)
Nordberg, Agneta (5)
Grimmer, Timo (5)
Drzezga, Alexander (5)
Mroczko, Barbara (5)
Waldemar, Gunhild (5)
Rabinovici, Gil D (5)
Rowe, Christopher C (5)
Cohen, Ann D (5)
Roe, Catherine M (5)
Koch, M. (5)
Peters, Oliver (5)
Maier, Wolfgang (5)
visa färre...
Lärosäte
Karolinska Institutet (34)
Göteborgs universitet (16)
Örebro universitet (10)
Lunds universitet (9)
Uppsala universitet (8)
Umeå universitet (2)
visa fler...
Kungliga Tekniska Högskolan (1)
Högskolan i Halmstad (1)
Stockholms universitet (1)
Högskolan i Gävle (1)
Linköpings universitet (1)
Chalmers tekniska högskola (1)
RISE (1)
visa färre...
Språk
Engelska (56)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (26)
Naturvetenskap (4)
Teknik (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy